期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 62, 期 8, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01018-18
关键词
ceftazidime-avibactam; colistin; Klebsiella pneumoniae; CRE; synergy; antagonism; Klebsiella
资金
- National Institutes of Health [K08AI114883, R21AI128338, R21AI111037]
- Allergan
We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25X, 1X, and 4X the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively. Colistin (2 mu g/m1) was bactericidal against 83% (12 h) and 42% (24 h) of the isolates. In combination, synergy and antagonism were identified against 13% and 46% of the isolates, respectively. The combination did not suppress ceftazidime-avibactam resistance. Colistin plus ceftazidime-avibactam did not provide a benefit over ceftazidime-avibactam against most CRE isolates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据